

October 30, 2019

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2019.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: as above



RPG Life Sciences Q2 PBT jumps 4-fold on YoY basis and consistent with Q1 PBT

Mumbai, 30 Oct, 2019: RPG Life Sciences Limited has announced its financial results for the quarter ended September 30th, 2019.

| | YoY Net Revenue from Operations | YoY PBT from Operations |
|---------------------|---|--|
| Q2 FY 20 Highlights | Rs 98.49 crores – up from Rs 90.5 crores | Rs 12.04 crores – up from Rs 3.10 crores |
| H1 FY 20 Highlights | Rs 192.53 crores – up from Rs 170.39 crores | Rs 22.90 crores – up from Rs 5.68 crores |

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted its Q2 and H1 results. Q2 results are consistent with those of Q1, with revenues higher than both the preceding and corresponding quarter last year and PBT registering a significant jump from Rs 3.01 crores to Rs 12.04 crores. Overall, during H1, company registered a 13% increase in revenue whereas company's PBT stood at Rs 22.90 crores versus Rs 5.68 crores marking a 4-fold jump over similar period last year.

"The overall performance of the company in H1 has been good. Q2 results are consistent with those of Q1. What has contributed to the turnaround performance is a slew of measures initiated such as focus on prescription demand generation, sales force effectiveness, product portfolio augmentation, sales health/hygiene and OPEX control. Domestic formulation business will continue to be the biggest contributor to the company performance and drive growth." said Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.

| H1 FY20 Other Highlights (y-o-y) | |
|----------------------------------|--|
| | 1. EBITDA margins improved from 8.7% to 16.5% |
| | 2. Domestic formulations sales grew over 23.2% with all major brands registering healthy double digit growth |
| | 3. API net sales grew by 13.8%. |
| | 4. Global ROW Sales grew by 32.2% |

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India's fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Group Communications

sumeet@rpg.in

+91 9820340650

